Zealand Pharma A/S (OTCMKTS:ZLDPF) Sees Significant Growth in Short Interest

Zealand Pharma A/S (OTCMKTS:ZLDPF) was the target of a large increase in short interest in December. As of December 31st, there was short interest totalling 1,166,300 shares, an increase of 39.7% from the December 15th total of 835,100 shares. Based on an average daily volume of 2,100 shares, the days-to-cover ratio is presently 555.4 days.

Analysts Set New Price Targets

Separately, JPMorgan Chase & Co. began coverage on Zealand Pharma A/S in a report on Friday, November 8th. They set an “overweight” rating for the company.

Zealand Pharma A/S Stock Performance

OTCMKTS ZLDPF opened at $98.32 on Friday. The company has a debt-to-equity ratio of 0.03, a current ratio of 35.49 and a quick ratio of 35.49. The stock has a 50 day moving average of $104.35 and a 200-day moving average of $118.89. Zealand Pharma A/S has a 12 month low of $64.42 and a 12 month high of $141.74.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.